In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From HitGen Inc.

Asia Deal Watch: HanAll, Daewoong Team With US Biotech In Parkinson's

Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.

Deal Watch Business Strategies

Asia Deal Watch: Biocytogen Antibody Candidates To Be Evaluated By ADC Therapeutics

Transactions involving Biocon/Zentiva, CrystalGenomics/PanGen, Umoja/IASO, Marinus/Tenacia, Ono/Captor and Daewoong/HitGen plus deals in brief.

Deal Watch Business Strategies

Finance Watch: VC Mega-Rounds Surge Again, Led By Acelyrin’s $300m Series C

Private Company Edition: Acelyrin will use its latest funding for Phase III development of izokibep in inflammatory diseases. Also, ArsenalBio raised $220m to take its programmable cell therapies into the clinic and RayzeBio’s $160m series D round will fund clinical trials for its radiopharmaceuticals. 

Financing Innovation

Korean Bioventures Suffer Q2 Financing Drought

Weak financing sentiment for Korean bioventures continues this year with sharply lower fund inflows from venture capital and other investors, as well as delayed or withdrawn IPOs, in Q2. Amyloid Solution, Rznomics, and UPPthera were among the top fundraisers.

South Korea Financing
See All

Company Information

  • Industry
  • Contract Research Organization-CRO
  • Distributors
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
      • Genomics-Proteomics
      • Molecular Diversity
  • Other Names / Subsidiaries
    • HitGen Pharmaceuticals Inc., Vernalis (R&D) Ltd.
UsernamePublicRestriction

Register